Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Merrimack Pharmaceuticals, Inc. Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock May 10, 2024 From Merrimack Pharmaceuticals, Inc. Via Business Wire Tickers MACK Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution May 09, 2024 From Merrimack Pharmaceuticals, Inc. Via Business Wire Tickers MACK Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution April 30, 2024 From Merrimack Pharmaceuticals, Inc. Via Business Wire Tickers MACK Merrimack Receives $225 Million Milestone Payment from Ipsen March 27, 2024 From Merrimack Pharmaceuticals, Inc. Via Business Wire Tickers MACK Merrimack Reports Full Year 2023 Financial Results March 07, 2024 From Merrimack Pharmaceuticals, Inc. Via Business Wire Tickers MACK Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) February 13, 2024 From Merrimack Pharmaceuticals, Inc. Via Business Wire Tickers MACK Merrimack Reports Third Quarter 2023 Financial Results November 02, 2023 From Merrimack Pharmaceuticals, Inc. Via Business Wire Tickers MACK Merrimack Reports Second Quarter 2023 Financial Results August 03, 2023 From Merrimack Pharmaceuticals, Inc. Via Business Wire Tickers MACK Merrimack Reports First Quarter 2023 Financial Results May 04, 2023 From Merrimack Pharmaceuticals, Inc. Via Business Wire Tickers MACK Merrimack Reports Full Year 2022 Financial Results March 09, 2023 From Merrimack Pharmaceuticals, Inc. Via Business Wire Tickers MACK Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan December 05, 2022 From Merrimack Pharmaceuticals, Inc. Via Business Wire Tickers MACK Merrimack Provides Ipsen Report That Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma November 09, 2022 From Merrimack Pharmaceuticals, Inc. Via Business Wire Merrimack Reports Third Quarter 2022 Financial Results November 03, 2022 From Merrimack Pharmaceuticals, Inc. Via Business Wire Tickers MACK Merrimack Reports Second Quarter 2022 Financial Results August 04, 2022 From Merrimack Pharmaceuticals, Inc. Via Business Wire Tickers MACK Merrimack Provides Ipsen Report of Results From Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer August 03, 2022 From Merrimack Pharmaceuticals, Inc. Via Business Wire Tickers MACK Merrimack Reports First Quarter 2022 Financial Results May 05, 2022 From Merrimack Pharmaceuticals, Inc. Via Business Wire Tickers MACK Merrimack Reports Third Quarter 2021 Financial Results November 04, 2021 From Merrimack Pharmaceuticals, Inc. Via Business Wire Tickers MACK Merrimack Reports Second Quarter 2021 Financial Results August 05, 2021 From Merrimack Pharmaceuticals, Inc. Via Business Wire Tickers MACK Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.